Literature DB >> 26719339

Configuration-dependent Presentation of Multivalent IL-15:IL-15Rα Enhances the Antigen-specific T Cell Response and Anti-tumor Immunity.

Enping Hong1, Ilana M Usiskin1, Cristina Bergamaschi2, Douglas J Hanlon3, Richard L Edelson3, Sune Justesen4, George N Pavlakis2, Richard A Flavell5, Tarek M Fahmy6.   

Abstract

Here we report a "configuration-dependent" mechanism of action for IL-15:IL-15Rα (heterodimeric IL-15 or hetIL-15) where the manner by which IL-15:IL-15Rα molecules are presented to target cells significantly affects its function as a vaccine adjuvant. Although the cellular mechanism of IL-15 trans-presentation via IL-15Rα and its importance for IL-15 function have been described, the full effect of the IL-15:IL-15Rα configuration on responding cells is not yet known. We found that trans-presenting IL-15:IL-15Rα in a multivalent fashion on the surface of antigen-encapsulating nanoparticles enhanced the ability of nanoparticle-treated dendritic cells (DCs) to stimulate antigen-specific CD8(+) T cell responses. Localization of multivalent IL-15:IL-15Rα and encapsulated antigen to the same DC led to maximal T cell responses. Strikingly, DCs incubated with IL-15:IL-15Rα-coated nanoparticles displayed higher levels of functional IL-15 on the cell surface, implicating a mechanism for nanoparticle-mediated transfer of IL-15 to the DC surface. Using artificial antigen-presenting cells to highlight the effect of IL-15 configuration on DCs, we showed that artificial antigen-presenting cells presenting IL-15:IL-15Rα increased the sensitivity and magnitude of the T cell response, whereas IL-2 enhanced the T cell response only when delivered in a paracrine fashion. Therefore, the mode of cytokine presentation (configuration) is important for optimal immune responses. We tested the effect of configuration dependence in an aggressive model of murine melanoma and demonstrated significantly delayed tumor progression induced by IL-15:IL-15Rα-coated nanoparticles in comparison with monovalent IL-15:IL-15Rα. The novel mechanism of IL-15 transfer to the surface of antigen-processing DCs may explain the enhanced potency of IL-15:IL-15Rα-coated nanoparticles for antigen delivery.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  CD8+ T cell; IL-15; IL-15 receptor α; T cell; antigen delivery; antigen presentation; dendritic cell; immunotherapy; nanoparticles; nanotechnology

Mesh:

Substances:

Year:  2015        PMID: 26719339      PMCID: PMC4861462          DOI: 10.1074/jbc.M115.695304

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  107 in total

1.  Dendritic cell-derived IL-15 controls the induction of CD8 T cell immune responses.

Authors:  René Rückert; Katja Brandt; Elena Bulanova; Farhad Mirghomizadeh; Ralf Paus; Silvia Bulfone-Paus
Journal:  Eur J Immunol       Date:  2003-12       Impact factor: 5.532

2.  Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors.

Authors:  Theodora Fifis; Anita Gamvrellis; Blessing Crimeen-Irwin; Geoffrey A Pietersz; Jie Li; Patricia L Mottram; Ian F C McKenzie; Magdalena Plebanski
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

3.  Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes.

Authors:  L Zitvogel; A Regnault; A Lozier; J Wolfers; C Flament; D Tenza; P Ricciardi-Castagnoli; G Raposo; S Amigorena
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

4.  Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy.

Authors:  Karlo Perica; Joan Glick Bieler; Christian Schütz; Juan Carlos Varela; Jacqueline Douglass; Andrew Skora; Yen Ling Chiu; Mathias Oelke; Kenneth Kinzler; Shibin Zhou; Bert Vogelstein; Jonathan P Schneck
Journal:  ACS Nano       Date:  2015-07-14       Impact factor: 15.881

Review 5.  Interleukin-15 biology and its therapeutic implications in cancer.

Authors:  Jason C Steel; Thomas A Waldmann; John C Morris
Journal:  Trends Pharmacol Sci       Date:  2011-10-25       Impact factor: 14.819

6.  Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting.

Authors:  Tarek M Fahmy; Robert M Samstein; Casey C Harness; W Mark Saltzman
Journal:  Biomaterials       Date:  2005-04-18       Impact factor: 12.479

7.  IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine.

Authors:  K Q Xin; K Hamajima; S Sasaki; T Tsuji; S Watabe; E Okada; K Okuda
Journal:  Vaccine       Date:  1999-02-26       Impact factor: 3.641

8.  TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis.

Authors:  Stacey L Demento; Nathalie Bonafé; Weiguo Cui; Susan M Kaech; Michael J Caplan; Erol Fikrig; Michel Ledizet; Tarek M Fahmy
Journal:  J Immunol       Date:  2010-07-26       Impact factor: 5.422

9.  Secretion and biological activity of short signal peptide IL-15 is chaperoned by IL-15 receptor alpha in vivo.

Authors:  Cristina Bergamaschi; Rashmi Jalah; Viraj Kulkarni; Margherita Rosati; Gen-Mu Zhang; Candido Alicea; Andrei S Zolotukhin; Barbara K Felber; George N Pavlakis
Journal:  J Immunol       Date:  2009-09-01       Impact factor: 5.422

10.  Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity.

Authors:  Samar Hamdy; Ommoleila Molavi; Zengshuan Ma; Azita Haddadi; Aws Alshamsan; Zahra Gobti; Sara Elhasi; John Samuel; Afsaneh Lavasanifar
Journal:  Vaccine       Date:  2008-08-03       Impact factor: 3.641

View more
  12 in total

Review 1.  T cell immunotherapy enhanced by designer biomaterials.

Authors:  Zachary S Dunn; John Mac; Pin Wang
Journal:  Biomaterials       Date:  2019-06-14       Impact factor: 12.479

2.  IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice.

Authors:  Yimin Shi; Lillia Dincheva-Vogel; Charles E Ayemoba; Jeffrey P Fung; Cristina Bergamaschi; George N Pavlakis; Farzin Farzaneh; Karin M L Gaensler
Journal:  Blood Adv       Date:  2018-11-27

3.  Protective Immune Responses Elicited by Deglycosylated Live-Attenuated Simian Immunodeficiency Virus Vaccine Are Associated with IL-15 Effector Functions.

Authors:  Satoru Watanabe; Masayuki Fujino; Yohei Saito; Nursarat Ahmed; Hirotaka Sato; Chie Sugimoto; Tomotaka Okamura; Kenichi Hanaki; Emi E Nakayama; Tatsuo Shioda; Kouji Matsushima; Aftab A Ansari; Francois Villinger; Kazuyasu Mori
Journal:  J Immunol       Date:  2020-08-03       Impact factor: 5.422

4.  The molecular landscape of glioma in patients with Neurofibromatosis 1.

Authors:  Fulvio D'Angelo; Michele Ceccarelli; Luciano Garofano; Jing Zhang; Véronique Frattini; Francesca P Caruso; Genevieve Lewis; Kristin D Alfaro; Luc Bauchet; Giulia Berzero; David Cachia; Mario Cangiano; Laurent Capelle; John de Groot; Francesco DiMeco; François Ducray; Walid Farah; Gaetano Finocchiaro; Stéphane Goutagny; Carlos Kamiya-Matsuoka; Cinzia Lavarino; Hugues Loiseau; Véronique Lorgis; Carlo E Marras; Ian McCutcheon; Do-Hyun Nam; Susanna Ronchi; Veronica Saletti; Romuald Seizeur; John Slopis; Mariona Suñol; Fanny Vandenbos; Pascale Varlet; Dominique Vidaud; Colin Watts; Viviane Tabar; David E Reuss; Seung-Ki Kim; David Meyronet; Karima Mokhtari; Hector Salvador; Krishna P Bhat; Marica Eoli; Marc Sanson; Anna Lasorella; Antonio Iavarone
Journal:  Nat Med       Date:  2018-12-10       Impact factor: 53.440

5.  CD215+ Myeloid Cells Respond to Interleukin 15 Stimulation and Promote Tumor Progression.

Authors:  Shouheng Lin; Guohua Huang; Yiren Xiao; Wei Sun; Yuchuan Jiang; Qiuhua Deng; Muyun Peng; Xinru Wei; Wei Ye; Baiheng Li; Simiao Lin; Suna Wang; Qiting Wu; Qiubin Liang; Yangqiu Li; Xuchao Zhang; Yilong Wu; Pentao Liu; Duanqing Pei; Fenglei Yu; Zhesheng Wen; Yao Yao; Donghai Wu; Peng Li
Journal:  Front Immunol       Date:  2017-12-04       Impact factor: 7.561

6.  Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer.

Authors:  Andrew Zloza; A Karolina Palucka; Lisa M Coussens; Philip J Gotwals; Mark B Headley; Elizabeth M Jaffee; Amanda W Lund; Arlene H Sharpe; Mario Sznol; Derek A Wainwright; Kwok-Kin Wong; Marcus W Bosenberg
Journal:  J Immunother Cancer       Date:  2017-09-19       Impact factor: 13.751

Review 7.  Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer.

Authors:  Charles B Chesson; Andrew Zloza
Journal:  Nanomedicine (Lond)       Date:  2017-11-03       Impact factor: 5.307

Review 8.  The era of bioengineering: how will this affect the next generation of cancer immunotherapy?

Authors:  Michele Graciotti; Cristiana Berti; Harm-Anton Klok; Lana Kandalaft
Journal:  J Transl Med       Date:  2017-06-19       Impact factor: 5.531

9.  The combination of neoantigen quality and T lymphocyte infiltrates identifies glioblastomas with the longest survival.

Authors:  Jing Zhang; Francesca P Caruso; Jason K Sa; Sune Justesen; Do-Hyun Nam; Peter Sims; Michele Ceccarelli; Anna Lasorella; Antonio Iavarone
Journal:  Commun Biol       Date:  2019-04-23

Review 10.  Nanoparticle-Based Therapies for Turning Cold Tumors Hot: How to Treat an Immunosuppressive Tumor Microenvironment.

Authors:  Giulio Giustarini; Andrea Pavesi; Giulia Adriani
Journal:  Front Bioeng Biotechnol       Date:  2021-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.